API and IP Newsletter
Contents FDA approvals in February 2021. General information. Novartis' Sandoz, with Aubagio generic in its sights, sues FDA to launch copycat first By April 28 decide on 2 TB drugs, Bombay HC tells Centre . Intellectual Property. FDA approvals in February 2021 Sr. Brand API FDA-approved use on approval date* 1 Pepaxto melphalan flufenamide 2/26/2021 For the treatment of certain patients with relapsed or refractory multiple myeloma 2 Nulibry fosdenopterin 2/26/2021 To treat patients with the rare genetic disease molybdenum cofactor deficiency Type A Press Release 3 Amondys 45 casimersen 2/25/2021 For the treatment of Duchenne muscular dystrophy Press Release 4 Cosela trilacicilib 02/12/21 To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer Press Release 5 Evkeeza evinacumab-dgnb 02/11/21 For the treatment of homozygous familial hypercholesterolemia 6 Ukoniq umbralisib 02/05/21 For the treatment of certain patients with marginal